$6.37−$0.0300 (−0.47%) on the dayAs of the close; data may be delayed.
LFCR price, last 12 months
$8.82$3.66$6.37
Daily closes over the last 260 trading sessions: −7.0%. Highest close $8.82 on , lowest $3.66 on . Market data may be delayed.
Key stats
Previous close
$6.40
Open
$6.39
Day range
$6.35 – $6.40
52-week range
$3.63 – $8.98
Volume
319.1K
Avg volume (20 days)
358.6K
Market cap
$243.4M
Performance
1W−0.5%
1M+0.3%
3M+40.4%
6M+29.6%
YTD−21.9%
1Y−14.7%
vs S&P 500, 1Y−18.8 pts
Technicals and fundamentals
About Lifecore Biomedical, Inc.
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.
Chart LFCR with indicators, scan for setups and get alerts
This page is open to everyone. A free ScanPro account adds the interactive parts, along with watchlists, paper trading with simulated money and the Academy's quizzes.
A full LFCR chart with indicator overlays, pattern markers and daily, weekly or intraday bars.
Scans of a whole index or list with 72 named conditions, 26 chart setups or a formula of your own.
Alerts and notifications when one fires on a stock you watch, on delayed market data.
Figures describe the past, not what the price will do next. Educational tools, not investment advice.
Technicals
RSI (14)59.3mid-range
vs 50-day average+6.3%
vs 200-day average+19.1%price above both averages
MACDBelow signal
Daily range (ATR)1.0%average true range, % of price
52w low $3.6352w high $8.98
Where price sits today against its own history. A description, not a forecast.
Valuation
P/E (trailing)—
P/E (forward)−8.9
PEG2.66
Price / sales—
Price / book−3.30
EV / EBITDA—
Company figures as of Nov 20, 2026.
Analysts
ConsensusHold3.0 on 1 (strong buy) to 5 (strong sell)
Analysts2
Average target$6.28−1.7% from today
Price targets are opinions and tend to lean optimistic. Only 2 analysts cover it, so one view moves the average.
Earnings
Next results, expectedaround Mar 15, 2027 (in 114 days)A year after its Mar 16, 2026 results release; the last came Nov 4, 2026. An estimate from its SEC filings, not a date the company announced.
Seasonality
-3.1
J
+0.6
F
-24.8
M
+16.4
A
+20.7
M
+7.6
J
+0.5
J
-11.2
A
+12.8
S
+0.8
O
+14.2
N
-8.4
D
Average return in each calendar month, Dec 31, 2022 to Oct 31, 2026. 4 years is 4 observations a month: too few to call a pattern, so read it as history, not a calendar to trade.
Year by year
Year
J
F
M
A
M
J
J
A
S
O
N
D
Year
2026
+6
−17
−48
+36
−1
+5
−16
+1
+48
−3
−22%
2025
−20
−2
+21
−4
+0
+20
−14
+9
−3
−2
+10
+4
+10%
2024
+5
+28
−36
+21
−9
−12
+23
−31
+13
+15
+30
+0
+20%
2023
−4
−7
−35
+13
+93
+18
+8
−24
−6
−7
+2
−14
−4%
2022
−24
−24%
Each year's monthly returns in %, the observations behind the averages. The last column compounds the year's months; a year the history only partly covers is faded.
Financials
As reported in the company's SEC filings. Latest: Q3 FY2026, ended Sep 30, 2026.
Free shows the latest quarter, the latest year and the last 12 months. Plus shows every period and the growth figures.See Plus
Figures are as each 10-Q and 10-K reported them, in the company's own fiscal calendar, not restated later. A company that changes how it reports a line can make one period look out of step with the rest. Growth compares the same period a year earlier and is left blank when the year before was a loss. Banks and insurers report no gross profit, so rows they don't file are left out. Every filing on SEC EDGAR
Company is under investigation for potential securities law violations and breach of fiduciary duties regarding its acquisition at $6.28 per share plus contingent value rights, raising concerns about fair dealing for shareholders.
The company is the defendant in a class action lawsuit involving alleged securities fraud during the period October 2020 to March 2024. The settlement of $3.75 million indicates legal liability and potential misconduct by company leadership, which is negative for shareholders and the company's reputation.
The company secured its third commercial site transfer in five months, demonstrating strong execution of its strategic plan. The agreement is expected to generate revenue within 24 months and contribute to the company's 12% 2029 revenue CAGR target. Management expressed confidence in leveraging market momentum and building a stronger growth portfolio. This represents successful business development and validates the company's shift toward lower-risk, late-stage programs.
Company issued significantly lower 2026 revenue guidance ($120-125M vs $141.4M in 2025), citing operational challenges including anticipated customer loss, inventory dynamics, and product launch delays. Stock declined 18% following disclosure, and the company is now subject to a securities law investigation.
The announcement is a routine corporate governance disclosure regarding employee equity compensation. While it indicates company growth through new hires, the news itself is administrative in nature with no material business impact, financial performance implications, or strategic developments mentioned.
Company signed a new master services agreement, expects to become commercial supplier of choice, and sees potential to become a top five commercial customer with a new partner
Tone is the news provider's automated reading of each article for this stock. It describes the article, not what the price will do.